Bupropion D9

Method development and validation of a novel anti-​depressant bupropion by RP-​HPLC
By Kumar, Anil; Agrawal, Dilip; Bansal, Mukesh
From Asian Journal of Pharmaceutical Research and Development (2020), 8(3), 211-223
 
MSn, LC-​MS-​TOF and LC-​PDA studies for identification of new degradation impurities of bupropion
By Bansal, Rohit; Saini, Balraj; Bansal, Yogita; Bansal, Gulshan
From Biomedical Chromatography (2013), 27(11), 1387-1397
 
Impurities in bupropion hydrochloride sustained-​release tablets
By Cheng, Shu-qiao; Cai, Mei; Chen, Min-hui; Wang, Yu
From Zhongnan Yaoxue (2013), 11(2), 89-92

Bupropion D9 is chemically 1-(3-Chlorophenyl)-2-((2-(methyl-d3)propan-2-yl-1,1,1,3,3,3-d6)amino)propan-1-one. Bupropion D9 is supplied with detailed characterization data compliant with regulatory guideline. Bupropion D9 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Bupropion.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.